靶向二代测序从痰标本和分离株鉴定分枝杆菌及预测耐药性的性能评估
该研究评估Deeplex Myc-TB靶向二代测序(tNGS)在78株分离株和102份痰标本中鉴定结核分枝杆菌复合群(MTBC)和非结核分枝杆菌(NTM)及预测MTBC耐药性的性能,并与参考表型和基因型方法比较。结果显示MTBC检测无效比例低于2.5%,但NTM检测无效比例较高,尤其在痰标本中超过50%;在可评估标本中,鉴定特异性为100%,分离株和痰标本对MTBC鉴定灵敏度分别为92.7%和97.6%,MTBC耐药型分类符合率分别为91.9%和90.8%,排除意义未明变异后提高至96.8%和97.3%。
要点
- Deeplex Myc-TB对MTBC鉴定和耐药预测在分离株和痰标本中均表现良好。
- NTM检测无效比例高,尤其痰标本超过50%,限制其对NTM的临床应用。
- 排除意义未明变异后,MTBC耐药型分类符合率提高至96.8%和97.3%。
核心结论
- Deeplex Myc-TB靶向二代测序对分离株和痰标本中的MTBC提供高度特异的鉴定和可靠的基因型耐药谱预测。
- 对稀有NTM物种和混合感染的鉴定仍具挑战性,但tNGS在快速分枝杆菌诊断中展现出显著前景。
研究设计与样本
- 研究评估Deeplex Myc-TB靶向二代测序 assay,使用78株分离株和102份痰标本。
- DNA文库在Illumina MiSeq上测序,结果按定义的可接受标准分析,并与参考表型和基因型方法比较性能。
主要发现
- MTBC检测无效比例低于2.5%,但NTM检测无效更频繁,尤其痰标本中超过50%。
- 在可评估分离株和痰标本中,对阴性/非目标生物的特异性为100%。
- 分离株鉴定灵敏度:MTBC 92.7%(38/41),快速生长分枝杆菌(RGM)100%(5/5),缓慢生长分枝杆菌(SGM)87.5%(14/16)。
- 痰标本鉴定灵敏度:MTBC 97.6%(41/42),SGM 70%(7/10),RGM 66%(2/3)。
- MTBC耐药型与参考药敏方法的分类符合率:分离株91.9%(489/532),痰标本90.8%(472/520);排除意义未明变异后分别提高至96.8%(489/505)和97.3%(472/485)。
关键数值与推荐
- 检测限研究确认已发表的阈值100-1,000 genomes/PCR在分离株和痰标本中均适用。
临床怎么用
- Deeplex Myc-TB可用于从分离株和痰标本中快速鉴定MTBC并预测基因型耐药,支持早期诊断和临床管理。
- 对NTM检测结果需谨慎解读,尤其痰标本中无效比例高,可能需结合其他方法。
局限性
- NTM检测无效比例较高,尤其痰标本中超过50%,限制其对NTM的可靠鉴定。
- 稀有NTM物种和混合感染的鉴定仍具挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate identification and genotypic drug resistance prediction in mycobacteria are essential for early diagnosis and appropriate clinical management. Targeted next-generation sequencing (tNGS) detects multiple genetic targets and enables direct testing from primary specimens. We evaluated identification using the Deeplex Myc-TB assay for Mycobacterium tuberculosis complex (MTBC) and nontuberculous mycobacteria (NTM) as well as MTBC drug-resistance prediction from 78 isolates and 102 sputum samples. DNA libraries were sequenced (Illumina MiSeq), and results were analyzed using defined acceptability criteria. Performance was compared against reference phenotypic and genotypic methods. Testing for MTBC was invalid in <2.5% of cases, but NTM testing was invalid more frequently, especially in sputum (>50%). Of the evaluable isolates/sputum, specificity was 100% for negative/nontarget organisms. Among isolates, sensitivity for organism identification was 92.7% (38/41) for MTBC, 100% (5/5) for rapidly growing mycobacteria (RGM), and 87.5% (14/16) for slowly growing mycobacteria (SGM). For sputum, sensitivity was 97.6% (41/42) for MTBC, 70% (7/10) for SGM, and 66% (2/3) for RGM. Categorical agreement of MTBC resistotypes against reference susceptibility methods was 91.9% (489/532) for isolates and 90.8% (472/520) for sputum, increasing to 96.8% (489/505) and 97.3% (472/485), respectively, when variants of unknown significance were excluded. Limit-of-detection studies confirmed published thresholds of 100-1,000 genomes/PCR in both isolates and sputum. Deeplex Myc-TB provides highly specific identification and reliable genotypic resistance profiling from isolates and sputum, especially for MTBC. While identification of rare NTM species and mixed infections remain challenging, tNGS demonstrates substantial promise for rapid mycobacterial diagnostics.IMPORTANCERapid and accurate diagnosis of mycobacterial infections is essential for initiating effective treatment, interrupting transmission, and improving patient outcomes. Traditional phenotypic methods for organism identification and antibiotic susceptibility testing are slow and may be unreliable for certain drugs. This study evaluates the Deeplex Myc-TB targeted next-generation sequencing assay to identify mycobacteria and resistance-associated mutations from the Mycobacterium tuberculosis complex (MTBC) for both isolates and clinical sputum. Our findings show strong correlation of MTBC identification and resistance markers compared with reference methods.
引用
- Kuss-Duerkop SK, Godo P, DeCurtis EK, et al. Performance of a targeted next generation sequencing assay for mycobacterial identification and drug resistance from sputum and isolates. J Clin Microbiol. 2026. PMID: 42283516. doi:10.1128/jcm.00106-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。